BOSTON, May 21, 2026 -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including...
Arthur Klausner to be a featured speaker at CED Biotech Forum: Trends in Exit Strategies.
News | 06. 18. 2007
